Market closed
CG Oncology/$CGON
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Ticker
$CGON
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
61
Website
CG Oncology Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$1.69
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$2B
52-week high
$50.23
52-week low
$25.77
Average daily volume
829K
Financial strength
Current ratio
35.322
Quick ratio
34.603
Long term debt to equity
0.013
Total debt to equity
0.055
Management effectiveness
Return on assets (TTM)
-15.69%
Return on equity (TTM)
-19.76%
Valuation
Price to revenue (TTM)
2,043.259
Price to book
3.78
Price to tangible book (TTM)
3.78
Price to free cash flow (TTM)
-19.218
Growth
Revenue change (TTM)
236.95%
Earnings per share change (TTM)
-88.25%
What the Analysts think about CG Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for CG Oncology stock.
CG Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CG Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CG Oncology News
AllArticlesVideos
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewsWire·2 weeks ago
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
Seeking Alpha·3 weeks ago
CG Oncology Announces Pricing of Public Offering
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for CG Oncology stock?
CG Oncology (CGON) has a market cap of $2B as of December 31, 2024.
What is the P/E ratio for CG Oncology stock?
The price to earnings (P/E) ratio for CG Oncology (CGON) stock is 0 as of December 31, 2024.
Does CG Oncology stock pay dividends?
No, CG Oncology (CGON) stock does not pay dividends to its shareholders as of December 31, 2024.
When is the next CG Oncology dividend payment date?
CG Oncology (CGON) stock does not pay dividends to its shareholders.
What is the beta indicator for CG Oncology?
CG Oncology (CGON) does not currently have a Beta indicator.